ES2137562T3 - Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina. - Google Patents

Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina.

Info

Publication number
ES2137562T3
ES2137562T3 ES95943238T ES95943238T ES2137562T3 ES 2137562 T3 ES2137562 T3 ES 2137562T3 ES 95943238 T ES95943238 T ES 95943238T ES 95943238 T ES95943238 T ES 95943238T ES 2137562 T3 ES2137562 T3 ES 2137562T3
Authority
ES
Spain
Prior art keywords
sub
sup
alkyl
hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95943238T
Other languages
English (en)
Inventor
Franco Buzzetti
Maria Gabriella Brasca
Antonio Longo
Dario Ballinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Application granted granted Critical
Publication of ES2137562T3 publication Critical patent/ES2137562T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

SE PRESENTAN NUEVOS DERIVADOS DE 3-ARILIDENO-2-OXINDOL HIDROSOLUBLE, QUE TIENEN ACTIVIDAD INHIBIDORA DE QUINASA TIROSINA, REPRESENTADOS POR LA FORMULA GENERAL (I), EN DONDE M ES CERO, 1 O 2, A ES UN ANILLO BICICLICO ELEGIDO ENTRE TETRALINA, NAFTALENO, QUINOLINA E INDOL, R{SUP,1} ES HIDROGENO, C{SUB,1}C{SUB,6}ALQUILO O C{SUB,2}-C{SUB,6}ALCANOILO; UNO DE R{SUB,2} Y R{SUB,3} INDEPENDIENTEMENTE ES HIDROGENO Y EL OTRO ES UN SUSTITUYENTE SELECCIONADO A PARTIR DE: UN GRUPO C{SUB,1}C{SUB,6}ALQUILO, SUSTITUIDO POR 1,2 O 3 GRUPOS HIDROXIDOS; SO{SUB,3}R{SUP,4} DONDE R{SUP,4} ES HIDROGENO O C{SUB,1}-C{SUB,6} ALQUILO NO SUSTITUIDO O SUSTITUIDO POR 1,2 O 3 GRUPOS HIDROXI; SO{SUB,2}NHR{SUP,5} DONDE R{SUP,5} ES COMO R{SUP,4} DEFINIDO ARRIBA O UN -(CH{SUB,2}){SUB,N}-N(C{SUB,1}C{SUB,6}ALQUILO){SUB,2}, GRUPO EN EL CUAL N ES 2 O 3, COOR{SUP,6} EN EL CUAL R{SUP,6} ES C{SUB,1}-C{SUB,6}ALQUILO NO SUSTITUIDO O SUSTITUIDO POR FENILO O POR 1,2 O 3 GRUPOS HIDROXI O FENILO; -CONHR{SUP,7} DONDE R{SUP,7} ES HIDROGENO, FENILO O C{SUB,1}-C{SUB,6}ALQUILO SUSTITUIDO POR 1,2 O 3 GRUPOS HIDROXI O POR FENILO; -NHSO{SUB,2}R{SUP,8} EN EL CUAL R{SUP,8} ES C{SUB,1}-C{SUB,6} ALQUILO O FENILO NO SUSTITUIDO O SUSTITUIDO POR HALOGENO O POR C{SUB,1}-C{SUB,4}ALQUILO; -N(R{SUP,9}){SUB,2}, NHR{SUP,9} O -OR{SUP,9} EN DONDE R{SUP,9} ES C{SUB,2}C{SUB,6}ALQUILO SUSTITUIDO POR 1,2 O 3 GRUPOS HIDROXI; NHCOR{SUP,10}, -OOCR{SUP,10} O -CH{SUB,2}OOCR{SUP,10} EN EL CUAL R{SUP,10} ES C{SUB,1}-C{SUB,6} ALQUILO SUSTITUIDO POR 1, 2 O 3 GRUPOS HIDROXI; -NHCONH{SUB,2}; -NH-C(NH{SUB,2})=NH; C(NH{SUB,2})=NH; -CH{SUB,2}NHC(NH{SUB,2})=NH; CH{SUB,2}NH{SUB,2}; -OPO(OH){SUB,2}; -CH{SUB,2}OPO(OH){SUB,2}; PO(OH){SUB,2}; O (A), (B), (C), O GRUPO (D), EN DONDE P ES 1, 2 O 3 Y Z ES -CH{SUB,2}-, -O- O (E), EN EL CUAL R{SUP,11} ES HIDROGENO O ES COMO R{SUP,9} DEFINIDO ARRIBA; Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS.
ES95943238T 1995-01-26 1995-12-22 Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina. Expired - Lifetime ES2137562T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501567.3A GB9501567D0 (en) 1995-01-26 1995-01-26 Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2137562T3 true ES2137562T3 (es) 1999-12-16

Family

ID=10768639

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95943238T Expired - Lifetime ES2137562T3 (es) 1995-01-26 1995-12-22 Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina.

Country Status (10)

Country Link
US (1) US5840745A (es)
EP (1) EP0752985B1 (es)
JP (1) JPH09510993A (es)
AU (1) AU697673B2 (es)
CA (1) CA2186508C (es)
DE (1) DE69511253T2 (es)
ES (1) ES2137562T3 (es)
GB (1) GB9501567D0 (es)
IL (1) IL116851A (es)
WO (1) WO1996022976A1 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1998024432A2 (en) * 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
EP1014953B1 (en) 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AU6887698A (en) * 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
HUP0004024A3 (en) * 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
EP1049786A2 (en) 1998-01-21 2000-11-08 Sugen, Inc. Human orthologues of wart
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
JP2002522009A (ja) 1998-04-14 2002-07-23 スージェン・インコーポレーテッド Ｓｔｅ−２０関連蛋白質キナーゼ
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1107758A2 (en) 1998-08-28 2001-06-20 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
EP1117397A1 (en) 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
CN1319090A (zh) * 1998-09-25 2001-10-24 贝林格尔英格海姆法玛公司 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
KR20010108024A (ko) 1998-12-17 2001-12-07 프리돌린 클라우스너, 롤란드 비. 보레르 단백질 키나제 억제제로서의 4,5-피라진옥신돌
CA2354591A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
CA2354510A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
AU3770000A (en) * 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
US20020010203A1 (en) 1999-12-22 2002-01-24 Ken Lipson Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
WO2001090326A2 (en) 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002002639A2 (en) 2000-07-05 2002-01-10 Pharmacia & Upjohn Company Human ion channels
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2003000251A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel idolinones and uses thereof
DE10134196B4 (de) * 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
BRPI1011506B8 (pt) 2009-03-20 2021-05-25 Vertex Pharma processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US20150064163A1 (en) 2011-09-02 2015-03-05 Lifenet Health BMP Peptides & Methods of Use
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
KR102268351B1 (ko) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 그의 용도
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
HUE056325T2 (hu) 2013-08-26 2022-02-28 Biontech Res And Development Inc SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
CA2960642A1 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
CN111675647B (zh) * 2020-06-26 2022-03-01 深圳技术大学 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3209271A1 (de) * 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5300655A (en) * 1989-04-18 1994-04-05 Pfizer Inc. 2-carboxy-thiophene derivatives
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

Also Published As

Publication number Publication date
WO1996022976A1 (en) 1996-08-01
AU4436396A (en) 1996-08-14
AU697673B2 (en) 1998-10-15
EP0752985B1 (en) 1999-08-04
CA2186508A1 (en) 1996-08-01
US5840745A (en) 1998-11-24
JPH09510993A (ja) 1997-11-04
EP0752985A1 (en) 1997-01-15
IL116851A0 (en) 1996-07-23
DE69511253D1 (de) 1999-09-09
GB9501567D0 (en) 1995-03-15
CA2186508C (en) 2006-10-31
DE69511253T2 (de) 2000-02-03
IL116851A (en) 2000-06-01

Similar Documents

Publication Publication Date Title
ES2137562T3 (es) Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina.
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
DE3882614D1 (de) Indol-derivate.
YU97292A (sh) N-fenilalanil i n-fenilglicil derivati dipeptida l-azetidin-2-karboksilne kiseline
FI830776A0 (fi) Nya foereningar, foerfarande foer deras framstaellning samt deras anvaendning som laekemedel
SE8201537L (sv) Nya 3,4-dihydro-5h-2,3-bensodiazepinderivat och forfarande for framstellning derav
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ATE17249T1 (de) 9-(2-(3-indolyl)aethyl)-1-oxa-4,9diazaspiro(5.5)undecan-3-one.
ES8203845A1 (es) Procedimiento para preparar derivados de piridoxina
EA200501104A1 (ru) Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция
ATE177080T1 (de) Indol derivate zur behandlung von migräne
RU94020400A (ru) Производные индола, способ их получения, фармацевтическая композиция, способ лечения головной боли
SE8403801L (sv) Nya bensotiazepiner med kardiovaskuler anvendbarhet, forfarande for framstellning derav och farmaceutiska kompositioner som innehaller dem
FI840635A (fi) Nya karbacykliner, foerfarande foer framstaellning av dem och deras anvaendning som laekemedel.
ES2125161B1 (es) Nuevos derivados de 2-(3h)-oxazolona.
PE25998A1 (es) DERIVADOS DE OCTAHIDRO-PIRROLO(1,2-a)-PIRAZINA 2,7-SUSTITUIDOS
US3524860A (en) (2-imidazolin-2-yl)alkyl-substituted 7-azaindoles
MX9304820A (es) Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
FI830893A0 (fi) Nya fenylpiperazin-derivat samt deras framstaellningsfoerfarande
ES8703427A1 (es) Procedimiento para la obtencion de compuestos de amida
ES2188029T3 (es) Fenil-alquil-imidazoles como antagonistas del receptor h3.
DK163301C (da) Indolderivater og fremgangsmaade til fremstilling samt anvendelse af samme
NO871339L (no) Fremgangsmaate for fremstilling av nye pyridin-karboksylsyrederivater
ES2140552T3 (es) Derivados indol como inhibidores de la 5-alfa-reductasa-1.
FI810632L (fi) 5,6:8,9-tetrahydro-7h-dibenz (d f)azoninderivat deras framstaellning och foereningar innehaollande dem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752985

Country of ref document: ES